"Metabolic syndrome" is a clinical shorthand for a cluster of cardiovascular risk factors that travel together: central obesity, elevated triglycerides, low HDL cholesterol, elevated blood pressure, and impaired fasting glucose. In the general population, having metabolic syndrome roughly doubles the risk of cardiovascular disease and quintuples the risk of type 2 diabetes. In schizophrenia, prevalence runs around 30–35%, compared with 20–25% in matched general-population samples (Vancampfort et al., 2015, World Psychiatry).
Metabolic syndrome is a cluster of five cardiometabolic risk factors that affects roughly one in three people on antipsychotics, substantially raises cardiovascular and diabetes risk, and is detectable, monitorable, and treatable — but only if someone is actually checking.
The definition
The most commonly used definition is the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, modified by the American Heart Association. Three or more of the following define metabolic syndrome (AHA/NHLBI Scientific Statement, 2005):
- Waist circumference: ≥ 102 cm (40 in) in men, ≥ 88 cm (35 in) in women (lower thresholds in some Asian populations)
- Triglycerides: ≥ 150 mg/dL (or on lipid-lowering treatment)
- HDL cholesterol: < 40 mg/dL in men, < 50 mg/dL in women (or on treatment)
- Blood pressure: ≥ 130/85 mmHg (or on antihypertensive treatment)
- Fasting glucose: ≥ 100 mg/dL (or on glucose-lowering treatment)
The International Diabetes Federation uses similar criteria but requires central obesity as a mandatory component.
Why it matters in schizophrenia
Cardiovascular disease is the leading cause of premature death in schizophrenia (see our cardiovascular disease article). Metabolic syndrome is the most common modifiable pathway to that outcome. The 2015 Vancampfort meta-analysis confirmed the elevated prevalence; multiple cohort studies have linked metabolic syndrome in this population to higher rates of myocardial infarction, stroke, and all-cause mortality.
Why prevalence is elevated
- Antipsychotic side effects — particularly olanzapine, clozapine, quetiapine, and to a lesser extent risperidone and paliperidone
- Illness-related metabolic vulnerability that pre-dates treatment
- High smoking rates contributing to dyslipidemia and insulin resistance
- Sedentary lifestyle, often shaped by negative symptoms and side effects
- Food environment and economic factors
What monitoring should look like
The 2004 American Diabetes Association/American Psychiatric Association consensus on antipsychotic monitoring (Consensus Statement, Diabetes Care, 2004) is the most widely cited framework:
- Baseline: personal/family history, weight/BMI, waist circumference, blood pressure, fasting glucose, fasting lipid profile
- Weeks 4, 8, 12 after starting: weight
- 3 months: blood pressure, fasting glucose, fasting lipids
- Quarterly thereafter: weight
- Annually: blood pressure, fasting glucose
- Every 5 years: repeat fasting lipids if baseline normal (more frequently if abnormal)
NICE guidance in the UK is broadly similar (NICE CG178: Psychosis and schizophrenia in adults). Real-world adherence to monitoring is poor across most health systems — multiple audits suggest fewer than half of patients receive guideline-concordant baseline metabolic screening.
What to do when criteria are met
Reassess the antipsychotic
If on a high-metabolic-burden agent, discuss with the prescriber whether a switch to a more weight-neutral option (aripiprazole, lurasidone, ziprasidone, lumateperone) is clinically reasonable. In treatment-resistant illness on clozapine, switching may not be possible — aggressive metabolic management is then the strategy.
Treat each component
- Hypertension: standard antihypertensive treatment; ACE inhibitors and ARBs are commonly first-line.
- Dyslipidemia: statin therapy when 10-year ASCVD risk crosses guideline thresholds, or for known cardiovascular disease, diabetes, or LDL ≥ 190 mg/dL.
- Impaired fasting glucose: lifestyle intervention; metformin if HbA1c continues to rise; treat as diabetes if criteria met.
- Central obesity: structured lifestyle program; consider metformin, GLP-1 agonists, or olanzapine/samidorphan if on olanzapine.
Address smoking
Smoking compounds every component of metabolic syndrome's cardiovascular impact. Cessation is the single highest-leverage intervention; varenicline, bupropion, and nicotine replacement all have evidence in this population.
Structured lifestyle support
Programs adapted for serious mental illness (ACHIEVE, STRIDE, In SHAPE) demonstrate sustained modest weight loss and metabolic improvement. They require intensity and continuity — short, low-dose interventions rarely work.
You experience chest pain, sudden severe headache, weakness on one side of the body, or symptoms of severe hyperglycemia (extreme thirst, confusion, vomiting). These can signal cardiovascular events or diabetic emergencies.
Who is responsible?
One of the structural problems in this area is that no single clinician owns metabolic monitoring. Psychiatrists prescribe the antipsychotic but may not feel comfortable managing lipids and blood pressure. Primary-care doctors may not see patients regularly. Pharmacists are increasingly involved, particularly in clozapine clinics and integrated behavioural health settings.
The most reliable models are integrated — physical health and mental health care delivered in the same setting, with shared records and a designated person responsible for cardiometabolic monitoring. Where that is not available, patients and families can advocate by asking explicitly at each visit: "When was my last lipid panel? When was my last fasting glucose?"
The big picture
Metabolic syndrome on antipsychotics is one of the more solvable parts of the schizophrenia mortality gap. The screening tests are cheap and standardised. The treatments are familiar and effective. The bottleneck is organisational — getting monitoring done, getting results acted on, and integrating physical and mental health care. Patients who track their own numbers, families who push for monitoring, and care systems that integrate primary and specialty care all contribute to closing the gap.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.